TSLP and asthma: The WAYPOINT phase 3, randomized, placebo-controlled trial evaluated the efficacy and safety of the anti-TSLP monoclonal antibody tezepelumab in patients with severe CRSwNP, with or without comorbid asthma (NCT04851964).